Selected article for: "alveolar injury and diffuse alveolar injury"

Author: Fireizen, Yaron; Shahriary, Cyrus; Imperial, Maria E.; Randhawa, Inderpal; Nianiaris, Nastasia; Ovunc, Bugsu
Title: Pediatric P‐ANCA vasculitis following COVID‐19
  • Cord-id: 9krkyuyq
  • Document date: 2021_8_11
  • ID: 9krkyuyq
    Snippet: BACKGROUND: Perinuclear anti‐neutrophil cytoplasmic antibodies (P‐ANCA) are associated with a multisystem vasculitis affecting small blood vessels in the body. A handful of adult patients who developed vasculitis post‐COVID‐19 have been reported. Although SARS‐CoV‐2 has been shown to drive an exaggerated immune response in the pediatric population, such as in Multisystem Inflammatory Syndrome in Children (MIS‐C), only one case of vasculitis following COVID‐19 has been reported pr
    Document: BACKGROUND: Perinuclear anti‐neutrophil cytoplasmic antibodies (P‐ANCA) are associated with a multisystem vasculitis affecting small blood vessels in the body. A handful of adult patients who developed vasculitis post‐COVID‐19 have been reported. Although SARS‐CoV‐2 has been shown to drive an exaggerated immune response in the pediatric population, such as in Multisystem Inflammatory Syndrome in Children (MIS‐C), only one case of vasculitis following COVID‐19 has been reported previously in children. CASE PRESENTATION: Seventeen‐year‐old male with a past medical history of COVID‐19 pneumonia two months prior presented with acute kidney injury and diffuse alveolar hemorrhage. Rheumatologic workup revealed P‐ANCA and Myeloperoxidase (MPO) positivity. Kidney biopsy showed necrotizing glomerulonephritis with limited immune complex deposition. Subsequently, he was treated with steroids and plasmapheresis, and ultimately started on cyclophosphamide. CONCLUSIONS: To our knowledge, this report presents the second reported pediatric case of P‐ANCA/MPO vasculitis following COVID‐19.

    Search related documents:
    Co phrase search for related documents
    • activation molecular mimicry and acute vasculitis: 1
    • activation molecular mimicry and lupus erythematosus: 1
    • acute infection and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16